<DOC>
	<DOCNO>NCT00630357</DOCNO>
	<brief_summary>A cohort patient become seizure-free add-on treatment one standard AED Keppra previous trial ( N01031 ) follow assess whether seizure freedom maintain . Tolerability document .</brief_summary>
	<brief_title>Trial Evaluate Safety Efficacy Keppra After Conversion Mono-therapy Subjects With Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Diagnosis epilepsy partial seizure ; complete trial N01031 Keppra adjunctive therapy ( SKATE ) ; seizurefree last 3 month prior protocol Visit 1 ; 1 concomitant market AED time trial entry throughout previous trial N01031 ; clinical judgment Investigator , progressive withdrawal concomitant AED conversion monotherapy Keppra attempt . History suicide attempt , current suicidal ideation , serious psychiatric disorder require require hospitalization medication within previous 5 year ; presence know pseudoseizures within last year ; presence history allergy component Keppra ( levetiracetam , lactose , cornstarch , excipients ) pyrrolidine derivative ; felbamate less 18 month exposure ; vigabatrin , without visual field assessment per recommendation manufacturer , i.e. , every 6 month ; uncountable seizure ( cluster ) history convulsive status epilepticus within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>